Yingying N. Du

Ji Xi Road
Hefei, 230022, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 81 publications

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.

Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study.

Journal: Future oncology (London, England)

Published: June 03, 2026

Bisbenzoselenophene[b]-Fused AzaBODIPYs as Strong Near-Infrared-Absorbing Photosensitizers for Effective Photodynamic Tumor Therapy.

Bisbenzoselenophene[b]-Fused AzaBODIPYs as Strong Near-Infrared-Absorbing Photosensitizers for Effective Photodynamic Tumor Therapy.

Journal: Journal of medicinal chemistry

Published: June 02, 2026

Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.

Peripheral Blood Biomarkers for Predicting the Efficacy of Neoadjuvant Immunochemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.

Journal: Journal of inflammation research

Published: May 22, 2026

KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion.

KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion.

Journal: Journal for immunotherapy of cancer

Published: May 04, 2026

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.

Journal: Lancet (London, England)

Published: April 23, 2026

Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation.

Aurora-A drives sorafenib resistance by scaffolding stress granule assembly via phase separation.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: April 20, 2026

Expert consensus on the detection and clinical application of tumor mutational burden.

Expert consensus on the detection and clinical application of tumor mutational burden.

Journal: Cancer biology & medicine

Published: February 18, 2026

Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer.

Targeting the TBK1-p62 condensate axis restores sensitivity to EGFR-TKIs in resistant lung cancer.

Journal: Protein & cell

Published: December 18, 2025

Machine learning-based prognostic model and single-cell transcriptomic integration for identifying brain metastasis-associated malignant subpopulations and potential therapeutic targets in lung adenocarcinoma.

Machine learning-based prognostic model and single-cell transcriptomic integration for identifying brain metastasis-associated malignant subpopulations and potential therapeutic targets in lung adenocarcinoma.

Journal: Cancer cell international

Published: November 06, 2025

Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance.

Integrative single-cell and bulk RNA sequencing unravels the role of ACTN1 in promoting lung cancer with brain metastasis and epidermal growth factor receptor-tyrosine kinase inhibitor resistance.

Journal: Frontiers in cell and developmental biology

Published: November 03, 2025

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.

Journal: Lancet (London, England)

Published: July 23, 2025

Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo.

Clinical features and recurrence risk prediction model in patients with idiopathic inflammatory myopathies-associated interstitial lung disease: a retrospective study from Ningbo.

Journal: Frontiers in medicine

Published: July 16, 2025

Showing 1-12 of 81

Last Updated: 09/26/2026